Purpose statement​

This educational page is meant to provide independent, balanced scientific information on the evolving role of Minimal Residual Disease (MRD) assessment in Multiple Myeloma (MM).​

​The aim is to update this page with more information throughout the year to further support healthcare professionals with disease‑state education, peer‑reviewed evidence, and scientific context around MRD methodologies, interpretation challenges, and ongoing research.​

Scientific webinar by Dr. Bruno Paiva​

Minimal Residual Disease (MRD) assessment has become an important topic in Multiple Myeloma research and clinical trials, driven by increasing treatment depth and advances in high‑sensitivity detection techniques, including flow‑ and sequencing‑based approaches, as well as functional and imaging adjuncts.​

​Early data emerging from ongoing clinical studies exploring MRD‑informed treatment strategies, alongside regulatory discussions around its ue as an intermediate endpoint in drug trials and evolving international recommendations by IMWG, EMN and EHA1, 2, continue to shape the role of MRD as a clinical trial endpoint and an evolving tool under investigation in patient management. ​

This webinar by Dr. Bruno Paiva, entitled “Next Generation Flow in Multiple Myeloma Clinical Trials”, reviews key scientific updates and relevant methodological and practical considerations in the context of MRD assessment in Multiple Myeloma.​